Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia.

Azorin JM, Spiegel R, Remington G, Vanelle JM, Péré JJ, Giguere M, Bourdeix I.

Am J Psychiatry. 2001 Aug;158(8):1305-13.

PMID:
11481167
2.

Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group.

Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P.

Am J Psychiatry. 1998 Apr;155(4):499-504.

PMID:
9545995
3.

Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.

Breier AF, Malhotra AK, Su TP, Pinals DA, Elman I, Adler CM, Lafargue RT, Clifton A, Pickar D.

Am J Psychiatry. 1999 Feb;156(2):294-8.

PMID:
9989566
4.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
5.

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.

Conley RR, Mahmoud R.

Am J Psychiatry. 2001 May;158(5):765-74. Erratum in: Am J Psychiatry 2001 Oct;158(10):1759.

PMID:
11329400
6.

Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study.

Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D.

J Clin Psychiatry. 1998 Oct;59(10):521-7.

PMID:
9818633
7.
8.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2002 Feb;159(2):255-62. Erratum in: Am J Psychiatry 2002 Dec;159(12):2132.

PMID:
11823268
9.

Risperidone in treatment-refractory schizophrenia.

Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC.

Am J Psychiatry. 1999 Sep;156(9):1374-9.

PMID:
10484947
10.

Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

Zhong KX, Sweitzer DE, Hamer RM, Lieberman JA.

J Clin Psychiatry. 2006 Jul;67(7):1093-103.

PMID:
16889453
11.

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.

Josiassen RC, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing WW, Shaughnessy RA.

Am J Psychiatry. 2005 Jan;162(1):130-6.

PMID:
15625211
12.

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.

Zink M, Kuwilsky A, Krumm B, Dressing H.

J Psychopharmacol. 2009 May;23(3):305-14. doi: 10.1177/0269881108089593. Epub 2008 Jun 18.

PMID:
18562423
13.

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M.

J Clin Psychiatry. 2004 Apr;65(4):551-6.

PMID:
15119920
14.

Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.

Modabbernia A, Rezaei F, Salehi B, Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha A, Akhondzadeh S.

CNS Drugs. 2013 Jan;27(1):57-65. doi: 10.1007/s40263-012-0022-1.

PMID:
23233269
15.

Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia.

Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K.

J Clin Psychopharmacol. 1995 Feb;15(1 Suppl 1):45S-51S.

PMID:
7537287
16.

Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.

de Lucena D, Fernandes BS, Berk M, Dodd S, Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, Belmonte-de-Abreu PS, Gama CS.

J Clin Psychiatry. 2009 Oct;70(10):1416-23. doi: 10.4088/JCP.08m04935gry. Erratum in: J Clin Psychiatry. 2011 Aug;72(8):1157.

PMID:
19906345
17.

Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.

Li H, Luo J, Wang C, Xie S, Xu X, Wang X, Yu W, Gu N, Kane JM.

Schizophr Res. 2014 Aug;157(1-3):112-9. doi: 10.1016/j.schres.2014.05.040. Epub 2014 Jul 1. Erratum in: Schizophr Res. 2014 Oct;159(1):256.

PMID:
24994555
18.

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.

Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM.

Schizophr Res. 2003 Jun 1;61(2-3):303-14.

PMID:
12729882
19.

Clozapine alone versus clozapine and risperidone with refractory schizophrenia.

Honer WG, Thornton AE, Chen EY, Chan RC, Wong JO, Bergmann A, Falkai P, Pomarol-Clotet E, McKenna PJ, Stip E, Williams R, MacEwan GW, Wasan K, Procyshyn R; Clozapine and Risperidone Enhancement (CARE) Study Group.

N Engl J Med. 2006 Feb 2;354(5):472-82.

20.

Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).

Vieta E, Herraiz M, Fernández A, Gastó C, Benabarre A, Colom F, Martínez-Arán A, Reinares M.

J Clin Psychiatry. 2001 Aug;62(8):623-30.

PMID:
11561935
Items per page

Supplemental Content

Write to the Help Desk